(Avapritinib was approved by the FDA as first-line therapy for patients with PDGFRA Exon 18 mutation, including D842V mutation, in January 2020, and was not approved or available at time of his initial GIST diagnosis). This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.